Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $167.09 billion. The enterprise value is $216.22 billion.
| Market Cap | 167.09B |
| Enterprise Value | 216.22B |
Important Dates
The last earnings date was Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | Nov 6, 2026 |
Share Statistics
Pfizer has 5.70 billion shares outstanding. The number of shares has increased by 0.46% in one year.
| Current Share Class | 5.70B |
| Shares Outstanding | 5.70B |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | +0.91% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 68.03% |
| Float | 5.69B |
Valuation Ratios
The trailing PE ratio is 41.77 and the forward PE ratio is 10.35.
| PE Ratio | 41.77 |
| Forward PE | 10.35 |
| PS Ratio | 2.63 |
| Forward PS | 2.71 |
| PB Ratio | 1.88 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.21 |
| P/OCF Ratio | 11.82 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.69, with an EV/FCF ratio of 18.38.
| EV / Earnings | 53.72 |
| EV / Sales | 3.41 |
| EV / EBITDA | 8.69 |
| EV / EBIT | 11.72 |
| EV / FCF | 18.38 |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.42 |
| Quick Ratio | 1.00 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 2.45 |
| Debt / FCF | 5.38 |
| Interest Coverage | 6.83 |
Financial Efficiency
Return on equity (ROE) is 4.47% and return on invested capital (ROIC) is 12.83%.
| Return on Equity (ROE) | 4.47% |
| Return on Assets (ROA) | 5.59% |
| Return on Invested Capital (ROIC) | 12.83% |
| Return on Capital Employed (ROCE) | 10.70% |
| Weighted Average Cost of Capital (WACC) | 5.39% |
| Revenue Per Employee | $848,320 |
| Profits Per Employee | $53,773 |
| Employee Count | 75,000 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.49 |
Taxes
In the past 12 months, Pfizer has paid $186.00 million in taxes.
| Income Tax | 186.00M |
| Effective Tax Rate | 4.37% |
Stock Price Statistics
The stock price has increased by +19.75% in the last 52 weeks. The beta is 0.30, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +19.75% |
| 50-Day Moving Average | 28.77 |
| 200-Day Moving Average | 26.92 |
| Relative Strength Index (RSI) | 48.29 |
| Average Volume (20 Days) | 34,406,750 |
Short Selling Information
The latest short interest is 137.82 million, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 137.82M |
| Short Previous Month | 155.20M |
| Short % of Shares Out | 2.42% |
| Short % of Float | 2.42% |
| Short Ratio (days to cover) | 4.20 |
Income Statement
In the last 12 months, Pfizer had revenue of $63.62 billion and earned $4.03 billion in profits. Earnings per share was $0.70.
| Revenue | 63.62B |
| Gross Profit | 47.65B |
| Operating Income | 18.49B |
| Pretax Income | 4.26B |
| Net Income | 4.03B |
| EBITDA | 24.94B |
| EBIT | 18.49B |
| Earnings Per Share (EPS) | $0.70 |
Balance Sheet
The company has $14.28 billion in cash and $63.41 billion in debt, with a net cash position of -$49.13 billion or -$8.62 per share.
| Cash & Cash Equivalents | 14.28B |
| Total Debt | 63.41B |
| Net Cash | -49.13B |
| Net Cash Per Share | -$8.62 |
| Equity (Book Value) | 89.30B |
| Book Value Per Share | 15.61 |
| Working Capital | 13.28B |
Cash Flow
In the last 12 months, operating cash flow was $14.17 billion and capital expenditures -$2.39 billion, giving a free cash flow of $11.79 billion.
| Operating Cash Flow | 14.17B |
| Capital Expenditures | -2.39B |
| Depreciation & Amortization | 6.44B |
| Net Borrowing | 1.75B |
| Free Cash Flow | 11.79B |
| FCF Per Share | $2.07 |
Margins
Gross margin is 74.90%, with operating and profit margins of 29.07% and 6.34%.
| Gross Margin | 74.90% |
| Operating Margin | 29.07% |
| Pretax Margin | 6.70% |
| Profit Margin | 6.34% |
| EBITDA Margin | 39.19% |
| EBIT Margin | 29.07% |
| FCF Margin | 18.52% |
Dividends & Yields
This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 5.87%.
| Dividend Per Share | $1.72 |
| Dividend Yield | 5.87% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 15 |
| Payout Ratio | 245.08% |
| FCF Payout Ratio | 83.18% |
| Buyback Yield | -0.46% |
| Shareholder Yield | 5.39% |
| Earnings Yield | 2.39% |
| FCF Yield | 7.04% |
Analyst Forecast
The average price target for Pfizer is $30.26, which is 3.22% higher than the current price. The consensus rating is "Hold".
| Price Target | $30.26 |
| Price Target Difference | 3.22% |
| Analyst Consensus | Hold |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | -3.98% |
| EPS Growth Forecast (3Y) | -8.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 2.25 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.25 |
| Piotroski F-Score | 7 |